Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Lung Neoplasms 1Lung Diseases 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Specimen Handling 9Tamoxifen 8Radiotherapy 6exemestane 3Radiation Dose Hypofractionation 3Radiation 3Letrozole 3Anastrozole 3Surveys and Questionnaires 2Sentinel Lymph Node Biopsy 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Patient Navigation 2Observation 2Metformin 2Mastectomy 2Magnetic Resonance Spectroscopy 2Genetic Testing 2Biopsy 2trastuzumab biosimilar HLX02 1ruxolitinib 1poly ICLC 1palbociclib 1fezolinetant 1elacestrant 1afimoxifene 1abemaciclib 1Trastuzumab 1Testosterone 1Tablets 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Intraductal, Noninfiltrating × Omacor × 1 year × Clear all
NCT06195306 2026-05-20

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

National Cancer Institute (NCI)

Phase 2 Recruiting
66 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡